{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:56:06Z","timestamp":1790034966135,"version":"4.0.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T00:00:00Z","timestamp":1158019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T00:00:00Z","timestamp":1158019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1111\/j.1365-2133.2006.07523.x","type":"journal-article","created":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T14:37:51Z","timestamp":1158071871000},"page":"1197-1200","source":"Crossref","is-referenced-by-count":74,"title":["Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases"],"prefix":"10.1093","volume":"155","author":[{"given":"K.","family":"Kerl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Saurat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,9,12]]},"reference":[{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2000.18.10.2152","article-title":"Primary cutaneous B-cell lymphoma: review and current concepts","volume":"18","author":"Pandolfino","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody","volume":"10","author":"Leget","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1008265313133","article-title":"Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group","volume":"9","author":"Tobinai","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera\u00ae)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H","article-title":"Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma","volume":"89","author":"Heinzerling","year":"2000","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/000155501750376339","article-title":"Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody","volume":"81","author":"Soda","year":"2001","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1440-0960.2004.00027.x","article-title":"Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases","volume":"45","author":"Kennedy","year":"2004","journal-title":"Australas J Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2230.2004.01659.x","article-title":"Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody","volume":"30","author":"Lacouture","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2005.01.093","article-title":"Treatment of primary cutaneous B-cell lymphoma with rituximab","volume":"52","author":"Fink-Puches","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2133.2005.06659.x","article-title":"Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation","volume":"153","author":"Gellrich","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archderm.136.3.374","article-title":"Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma","volume":"136","author":"Heinzerling","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1046\/j.1365-2133.2001.04241.x","article-title":"Intralesional rituximab for cutaneous B-cell lymphoma","volume":"144","author":"Paul","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07523.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2133.2005.06433.x","article-title":"Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma","volume":"152","author":"Roguedas","year":"2005","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2006.07523.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2006.07523.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2006.07523.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:18:57Z","timestamp":1676384337000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/155\/6\/1197\/6637297"}},"subtitle":["Intralesional vs. intravenous rituximab for CBCL"],"short-title":[],"issued":{"date-parts":[[2006,9,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,12]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07523.x","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9,12]]}}}